Ozempic craze reshapes weight-loss culture, spurs demand crisis
Kamran Khan reflects on the global demand for the drug, as craze strains supplies for diabetes patients
The world’s obsession with slimness has found a new ally: Ozempic. Originally developed to treat Type 2 diabetes, the drug has become a global phenomenon as a weight-loss solution. From Hollywood celebrities to South Asian politicians, the injectable medication is driving a cultural shift in body image—and sparking ethical and supply concerns.
According to The Lancet, over one billion people worldwide suffer from obesity, with rates quadrupling since 1990. As a result, demand for Ozempic has skyrocketed. Google searches for “Ozempic weight loss” have surged by 200% over the past year, fueled by endorsements from influencers and stars.
The drug’s active ingredient, semaglutide, regulates blood sugar, boosts metabolism, and reduces appetite, making it a “miracle” fat-burning solution for many.
However, the soaring popularity comes with downsides. In the United States, prescriptions for Ozempic have risen 300% since 2020, with 60% of orders coming from non-diabetics.
This trend has created a supply crunch, leaving diabetes patients struggling to obtain the medication they rely on. Complaints of shortages, price hikes, and counterfeit products have emerged from the Middle East to Asia.
Novo Nordisk, the Danish company behind Ozempic, has reaped enormous financial rewards. Its 2023 revenue grew 154%, with $14 billion attributed to Ozempic sales alone.
Analysts project the drug’s market could reach $100 billion by 2030. Yet this success has drawn criticism, with activists warning about the growing divide between medical necessity and cosmetic use.
As social media amplifies the trend, health experts caution against bypassing traditional weight-loss methods like exercise and healthy eating. Medical professionals urge users to follow proper prescriptions and remain mindful of potential side effects.
The Ozempic craze highlights the intersection of health, culture, and commerce—raising questions about where the line should be drawn between medical innovation and lifestyle indulgence.
Comments
See what people are discussing